Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.85 USD
Change Today +0.07 / 1.03%
Volume 114.4K
As of 5:20 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

aethlon medical inc (AEMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/24/14 - $36.00
52 Week Low
06/4/15 - $6.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AETHLON MEDICAL INC (AEMD)

Related News

No related news articles were found.

aethlon medical inc (AEMD) Related Businessweek News

No Related Businessweek News Found

aethlon medical inc (AEMD) Details

Aethlon Medical, Inc., a medical device company, focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company’s Aethlon Hemopurifier addresses antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It is also developing exosome-based products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The company was founded in 1991 and is based in San Diego, California.

8 Employees
Last Reported Date: 08/5/15
Founded in 1991

aethlon medical inc (AEMD) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $442.5K
President and Director
Total Annual Compensation: $272.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $237.8K
Chief Science Officer and Vice President
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2015.

aethlon medical inc (AEMD) Key Developments

Aethlon Medical Extends Contract with the Defense Advanced Research Projects Agency

Aethlon Medical, Inc. announced that it has entered into an extension of its contract with the Defense Advanced Research Projects Agency, or DARPA, part of the Department of Defense. The Company originally entered into the initial DARPA contract on September 30, 2011. DARPA entered into this contract extension in order to exercise its option to continue the contract for year five, the final year of the contract. Under the DARPA contract, the company has been engaged to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The award from the Defense Advanced Research Projects Agency is a fixed-price contract that requires the achievement of multiple, incremental milestones to receive the full award during each year of the contract. The Company has achieved 23 milestones under the contract, which have resulted in revenues of approximately $4,872,000.

Aethlon Medical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Aethlon Medical, Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company's government contract revenue was $192,508 compared to $51,296 a year ago. The increase was due to achieving a milestone under the company’s DARPA contract in the 2016 period. Operating loss was $1,089,971 compared to $1,172,008 a year ago. Net loss before non-controlling interests was $1,216,659 compared to $3,704,292 a year ago. Net loss attributable to common stockholders was $1,183,036 compared to $3,655,941 a year ago. Basic and diluted net loss available to common stockholders per share was $0.18 compared to $0.80 a year ago.

Aethlon Medical, Inc. to Report Q1, 2016 Results on Aug 13, 2015

Aethlon Medical, Inc. announced that they will report Q1, 2016 results on Aug 13, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEMD:US $6.85 USD +0.07

AEMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEMD.
View Industry Companies

Industry Analysis


Industry Average

Valuation AEMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 50.4x
Price/Book 10.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 50.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETHLON MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at